Volume 20, Number 5—May 2014
Research
Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
Table 1
Characteristic | % Case-patient samples not tested, n = 683 | % Case-patient samples tested, n = 588 |
---|---|---|
Age, y | ||
<50 | 18.4 | 18.5 |
50–59 | 32.1 | 33.7 |
60–69 | 27.5 | 27.6 |
≥70 |
22.0 |
20.2 |
Race/ethnicity | ||
Asian/Pacific Islander | 1.3 | 4.4 |
Non-Hispanic Black | 11.9 | 12.6 |
Hispanic | 8.6 | 6.8 |
Non-Hispanic White | 77.6 | 75.2 |
Other |
0.6 |
1.0 |
Sex | ||
F | 23.4 | 25.4 |
M |
76.6 |
74.5 |
Cancer stage | ||
Local | 13.6 | 19.2 |
Regional | 52.0 | 56.5 |
Distant | 17.7 | 13.6 |
Unknown |
16.7 |
10.7 |
*Samples were provided from 7 US registries. |
1Members of HPV Typing of Cancers Workgroup who contributed to this study are listed at the end of this article.
Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.